Marker Therapeutics, Inc., a clinical-stage immuno-oncology company focusing on next-generation T cell immunotherapies, announced that CEO Dr. Juan Vera will participate in a live webcast on May 28, ...
Marker Therapeutics (MRKR) reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, ...
HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...
Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...
In the treatment of aggressive lymphomas and blood cancer (leukemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken ...
B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to ...
Marker Therapeutics Inc MRKR released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in ...
In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results